Cantex Pharmaceuticals
PrivateLast Round
Series D
Nov 12, 2014
Total Funding Raised
$30.92M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Cantex Pharmaceuticals is a biotechnology company that develops biopharmaceutical technologies designed to improve the treatment of cancers and other life-threatening disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cantex Pharmaceuticals Comparables
Compare Cantex Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| RAGE Biotech | 77% | |
| Arrowhead Pharmaceuticals | 69% | |
| RAPT Therapeutics | 66% |
Cantex Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Nov 12, 2014 | ||||
| Series C | Apr 11, 2014 | ||||
| Grant | Nov 3, 2010 | ||||
| Series B | Aug 25, 2006 | ||||
| Series A | Aug 12, 2002 |
Key People
Founding team and executive leadership
Cantex Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Research Corporation Technologies | Series B, Series C, Series A |
| Domain Associates | Series B, Series C, Series D |
| CHL Medical Partners | Series B, Series C |
| The Aurora Funds | Series B, Series C, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 31% MoM.
- Jun 20, 2026
Monthly visitors grew 31% MoM, reaching 1.9K.
Cantex Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Cantex Pharmaceuticals's valuation, stock price, and market status.
Is Cantex Pharmaceuticals a public or private company?
Cantex Pharmaceuticals is a private company.
What is the current stock price of Cantex Pharmaceuticals?
Cantex Pharmaceuticals is a private company with no public stock price. No recent secondary market data is available.
How much is Cantex Pharmaceuticals worth (valuation)?
Valuation information for Cantex Pharmaceuticals is not publicly available.
Can I buy Cantex Pharmaceuticals stock?
Cantex Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Cantex Pharmaceuticals's last funding round?
Cantex Pharmaceuticals's most recent funding round was Series D on November 12, 2014.
Who are the main investors in Cantex Pharmaceuticals?
Key investors in Cantex Pharmaceuticals include Domain Associates.
Will Cantex Pharmaceuticals IPO soon?
No public IPO plans have been announced for Cantex Pharmaceuticals.
How can I track Cantex Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Cantex Pharmaceuticals's secondary market activity and sign up for updates.